BioLineRX
BLRX
17 hedge funds and large institutions have $302K invested in BioLineRX in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 4 closing their positions.
979% more capital invested
Capital invested by funds: $28K → $302K (+$274K)
928% more call options, than puts
Call options by funds: $596K | Put options by funds: $58K
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
42% more funds holding
Funds holding: 12 → 17 (+5)
1.55% more ownership
Funds ownership: 0% → 1.55% (+1.6%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$55.3K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$52.2K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$51.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$41K |
| 5 |
Citigroup
New York
|
+$14.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$5.17K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$4.62K |
| 3 |
Morgan Stanley
New York
|
-$2.59K |
| 4 |
JP Morgan Chase
New York
|
-$1.11K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$292 |
BLRX Hedge Fund Activity: Q2 2025 in Review
17 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2025, worth a combined $302K — up 979% from $28K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BLRX positions and 4 closed out — a net gain of 5 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $55.3K. The largest seller was BNP Paribas Financial Markets, exiting entirely with an estimated $5.17K sold.
- 17 institutional investors held BioLineRX (BLRX) as of Q2 2025, up from 12 in Q1 2025.
- Funds reported $302K of BioLineRX stock for Q2 2025, up 979% quarter-over-quarter.
- 9 funds opened new BioLineRX positions in Q2 2025 and 4 closed out, a net change of +5 holders.
- The largest BioLineRX buyer in Q2 2025 was Citadel Advisors, an estimated $55.3K added.
- The largest BioLineRX seller in Q2 2025 was BNP Paribas Financial Markets, an estimated $5.17K sold.
Based on aggregated 13F filings for Q2 2025.